Richard S Finn

24PUBLICATIONS
171CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jun 10, 2026
Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.

|Mar 07, 2026
Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care.

Adam M Brufsky, Richard S Finn, Otto Metzger

|Mar 02, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.

Richard S Finn, Masatoshi Kudo, Ivan Borbath

|Feb 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study.

Stephen L Chan, Thomas Yau, Robin K Kelley

|Nov 19, 2024
Interventional Oncology Meets Immuno-oncology: Combination Therapies for Hepatocellular Carcinoma.

Ryan Bitar, Riad Salem, Richard Finn

|Aug 28, 2024
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas

Pageof 4

Frequent Collaborators

6 joint publications

Masatoshi Kudo

4 joint publications

Arndt Vogel

4 joint publications

Robin Kate Kelley

3 joint publications

Josep M Llovet